Annual Accounts Payable
$17.29 M
-$2.53 M-12.78%
December 1, 2023
Summary
- As of February 8, 2025, SVA annual accounts payable is $17.29 million, with the most recent change of -$2.53 million (-12.78%) on December 1, 2023.
- During the last 3 years, SVA annual accounts payable has fallen by -$13.25 million (-43.39%).
- SVA annual accounts payable is now -70.49% below its all-time high of $58.59 million, reached on December 31, 2021.
Performance
SVA Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$641.58 M
+$624.29 M+3610.48%
June 1, 2024
Summary
- As of February 8, 2025, SVA quarterly accounts payable is $641.58 million, with the most recent change of +$624.29 million (+3610.48%) on June 1, 2024.
- Over the past year, SVA quarterly accounts payable has dropped by -$177.95 million (-21.71%).
- SVA quarterly accounts payable is now -33.09% below its all-time high of $958.87 million, reached on June 30, 2021.
Performance
SVA Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
SVA Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -12.8% | -21.7% |
| 3 y3 years | -43.4% | -33.1% |
| 5 y5 years | +212.7% | +10000.0% |
SVA Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -70.5% | at low | -21.7% | +3610.5% |
| 5 y | 5-year | -70.5% | +199.0% | -33.1% | >+9999.0% |
| alltime | all time | -70.5% | >+9999.0% | -33.1% | >+9999.0% |
Sinovac Biotech Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2024 | - | $641.58 M(+3610.5%) |
| Dec 2023 | $17.29 M(-12.8%) | $17.29 M(-97.9%) |
| Jun 2023 | - | $819.53 M(+4033.8%) |
| Dec 2022 | $19.82 M(-66.2%) | $19.82 M(-94.1%) |
| Jun 2022 | - | $334.29 M(+470.6%) |
| Dec 2021 | $58.59 M(+91.8%) | $58.59 M(-93.9%) |
| Jun 2021 | - | $958.87 M(+3039.4%) |
| Dec 2020 | $30.54 M(+428.2%) | $30.54 M(-73.9%) |
| Sep 2020 | - | $117.00 M(+65.2%) |
| Jun 2020 | - | $70.83 M(+52.6%) |
| Mar 2020 | - | $46.41 M(+702.6%) |
| Dec 2019 | $5.78 M(+4.6%) | $5.78 M(-89.5%) |
| Sep 2019 | - | $55.19 M(+0.1%) |
| Jun 2019 | - | $55.11 M(+18.2%) |
| Mar 2019 | - | $46.62 M(+743.1%) |
| Dec 2018 | $5.53 M(-18.4%) | $5.53 M(-91.9%) |
| Jun 2018 | - | $68.43 M(+909.4%) |
| Dec 2017 | $6.78 M(+269.7%) | $6.78 M(-86.8%) |
| Jun 2017 | - | $51.54 M(+2710.4%) |
| Dec 2016 | $1.83 M(+6.9%) | $1.83 M(-93.0%) |
| Sep 2016 | - | $26.03 M(+18.0%) |
| Jun 2016 | - | $22.05 M(-2.9%) |
| Mar 2016 | - | $22.72 M(+1224.8%) |
| Dec 2015 | $1.72 M(-43.5%) | $1.72 M(-90.7%) |
| Sep 2015 | - | $18.44 M(-5.7%) |
| Jun 2015 | - | $19.57 M(+5.4%) |
| Mar 2015 | - | $18.57 M(+512.1%) |
| Dec 2014 | $3.03 M(-50.0%) | $3.03 M(-87.0%) |
| Sep 2014 | - | $23.33 M(-4.3%) |
| Jun 2014 | - | $24.38 M(-8.1%) |
| Mar 2014 | - | $26.53 M(+337.6%) |
| Dec 2013 | $6.06 M | $6.06 M(-76.9%) |
| Sep 2013 | - | $26.26 M(-1.0%) |
| Jun 2013 | - | $26.52 M(-1.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2013 | - | $26.86 M(+1137.9%) |
| Dec 2012 | $2.17 M(-26.3%) | $2.17 M(-92.1%) |
| Sep 2012 | - | $27.53 M(-4.1%) |
| Jun 2012 | - | $28.70 M(+12.5%) |
| Mar 2012 | - | $25.52 M(+766.4%) |
| Dec 2011 | $2.95 M(+29.5%) | $2.95 M(-86.3%) |
| Sep 2011 | - | $21.52 M(+14.2%) |
| Jun 2011 | - | $18.85 M(-3.9%) |
| Mar 2011 | - | $19.61 M(+762.7%) |
| Dec 2010 | $2.27 M(-40.0%) | $2.27 M(-86.1%) |
| Sep 2010 | - | $16.37 M(+35.0%) |
| Jun 2010 | - | $12.12 M(+8.6%) |
| Mar 2010 | - | $11.16 M(+194.5%) |
| Dec 2009 | $3.79 M(+176.5%) | $3.79 M(-73.6%) |
| Sep 2009 | - | $14.35 M(+22.1%) |
| Jun 2009 | - | $11.76 M(+20.1%) |
| Mar 2009 | - | $9.79 M(+614.2%) |
| Dec 2008 | $1.37 M(+76.7%) | $1.37 M(-88.8%) |
| Sep 2008 | - | $12.23 M(-12.2%) |
| Jun 2008 | - | $13.93 M(+32.3%) |
| Mar 2008 | - | $10.53 M(+1256.9%) |
| Dec 2007 | $775.90 K(+18.4%) | $775.90 K(-92.0%) |
| Sep 2007 | - | $9.68 M(+26.1%) |
| Jun 2007 | - | $7.68 M(+1071.3%) |
| Dec 2006 | $655.40 K(-5.9%) | $655.40 K(-35.4%) |
| Jun 2006 | - | $1.01 M(+45.7%) |
| Dec 2005 | $696.50 K(+107.4%) | $696.50 K(-74.0%) |
| Jun 2005 | - | $2.68 M(+698.7%) |
| Dec 2004 | $335.80 K(-77.4%) | $335.80 K(-78.7%) |
| Sep 2004 | - | $1.58 M(+2.9%) |
| Jun 2004 | - | $1.54 M(+3.5%) |
| Dec 2003 | $1.48 M(+2262.6%) | $1.48 M |
| Apr 2002 | $62.80 K(+48.1%) | - |
| Apr 2001 | $42.40 K(+14.0%) | - |
| Apr 2000 | $37.20 K | - |
FAQ
- What is Sinovac Biotech annual accounts payable?
- What is the all time high annual accounts payable for Sinovac Biotech?
- What is Sinovac Biotech annual accounts payable year-on-year change?
- What is Sinovac Biotech quarterly accounts payable?
- What is the all time high quarterly accounts payable for Sinovac Biotech?
- What is Sinovac Biotech quarterly accounts payable year-on-year change?
What is Sinovac Biotech annual accounts payable?
The current annual accounts payable of SVA is $17.29 M
What is the all time high annual accounts payable for Sinovac Biotech?
Sinovac Biotech all-time high annual accounts payable is $58.59 M
What is Sinovac Biotech annual accounts payable year-on-year change?
Over the past year, SVA annual accounts payable has changed by -$2.53 M (-12.78%)
What is Sinovac Biotech quarterly accounts payable?
The current quarterly accounts payable of SVA is $641.58 M
What is the all time high quarterly accounts payable for Sinovac Biotech?
Sinovac Biotech all-time high quarterly accounts payable is $958.87 M
What is Sinovac Biotech quarterly accounts payable year-on-year change?
Over the past year, SVA quarterly accounts payable has changed by -$177.95 M (-21.71%)